Poster Abstract Session:
108. Antimicrobials: Novel Agents
Friday, October 4, 2013: 12:30 PM-2:00 PM
Room: The Moscone Center: Poster Hall C

Learning Objectives:

-

Target Audience: academicians

Presentations:

702
Efficacy and safety of telavancin in the treatment of Gram-positive bloodstream infections in cancer patients
Ray Hachem, MD ; Anne-Marie Chaftari, MD ; Aline El Zakhem, MD ; George M. Viola, MD, MPH ; Bruno Granwehr, MD ; Andrew Gagel ; Ying Jiang, MS ; Munirah Alshuaibi, MD ; Issam Raad, MD

704
Activity of Solithromycin and Comparators against Streptococci Isolated from Respiratory Samples Collected in 2012
Ian Morrissey, PhD ; Prabhavathi Fernandes, PhD ; Claudina Tacchini, MSPHR ; Claudia Zampaloni, PhD ; Stephen Hawser, PhD

705
Microbiological and Cytotoxic Evaluation of Hyaluronidase-Degradable Nanocapsules Containing Polyhexanide Targeted for Burn Wound Treatment
Verena Gruetzner ; Nina Dohm ; Grit Baier, PhD ; Ron Unger, PhD ; Lars Choritz, MD ; Renate Foerch, PhD ; James Kirkpatrick, MD PhD ; Katharina Landfester, PhD ; Bernd Jansen, MD, PhD

708
A Phase I, Open-Label, Safety and Pharmacokinetic Study to Assess Bronchopulmonary Disposition of Intravenous Eravacycline (TP-434) in Healthy Men and Women
Kevin P. Connors, PharmD ; J. Samuel Pope, MD ; John Russomanno, MD ; Edward Salerno, MD ; Eric Shore, MD ; Seth T. Housman, PharmD, MPA ; David P. Nicolau, PharmD, FCCP, FIDSA

709
High-throughput Screening (HTS) for anti-infectives using a Whole Animal Infection Model
Raj Mohan Raja Muthiah, Ph.D. ; Beth Fuchs, Ph.D. ; Jonah Larkins-Ford ; Annie Connery ; Frederick Ausubel, PhD ; Eleftherios Mylonakis, MD, PhD
Posters
  • IDSA poster 2013.pdf (820.7 kB)

  • 710
    Oral Spray Formulation Forms a Barrier That Traps and Kills Airborne Transmitted Microorganisms
    Mahmoud Ghannoum, PhD ; Jyostna Chandra, PhD ; Afif Ghannoum ; Brian Sokol ; Pranab Mukherjee, PhD

    711
    A novel non abrasive, odorless andáeffective surface disinfectant
    Rahman Hariri, PhD, MBA, MT(ASCP) ; Scott Curry ; Juliet Ferrelli, MS, MT(ASCP), CIC ; Mohamed Yassin, MD, PhD

    713
    Summary of Comparative Ceftaroline Activity against Major Bacterial Pathogens in Russia: Results of Multicenter Study
    Roman Kozlov, MD, MSc, PhD ; Marina Sukhorukova, MD, PhD ; Mikhail Edelstein, PhD ; Andrey Dekhnich, MD, MSc, PhD

    714
    Sofosbuvir and Peginterferon alfa-2a/RibavirinTreatment of na´ve Genotype 1-4 HCV infected patients that are co-infected with HIV
    Maribel Rodriguez-Torres, MD ; Jose Rodriguez-Orengo, PhD ; Anuj Gaggar, MD, PhD ; William Symonds, PharmD ; John Mchutchison, MD ; Milagros Gonzalez, MD

    715
    Optimization of an Interferon-free Hepatitis C Virus Treatment Regimen Containing the NS3/4A Protease Inhibitor Faldaprevir, the Non-nucleoside NS5B Inhibitor BI207127, and Ribavirin for Genotype 1b-infected Patients
    Parvez Mantry, MD ; Marcus Schuchmann, MD ; Ansgar Lohse, MD ; Keikawus Arasteh, MD ; Michael Manns, MD ; Thomas Berg, MD ; Stefan Mauss, MD ; Michael Geissler, MD ; Wulf Bocher, MD ; Stefan Zeuzem, MD

    CME Credits:

    ACPE Credits:

    ACPE Number:


    Findings in the abstracts are embargoed until 12:01 a.m. PST, Oct. 2nd with the exception of research findings presented at the IDWeek press conferences.